Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Taysha Gene Therapies (TSHA) Other financing activities (2022 - 2025)

Taysha Gene Therapies' Other financing activities history spans 4 years, with the latest figure at -$285000.0 for Q3 2025.

  • For Q3 2025, Other financing activities changed N/A year-over-year to -$285000.0; the TTM value through Sep 2025 reached -$432000.0, down 1128.57%, while the annual FY2024 figure was -$167000.0, 27.07% up from the prior year.
  • Other financing activities for Q3 2025 was -$285000.0 at Taysha Gene Therapies, down from $118000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $1.1 million in Q4 2022 and bottomed at -$533000.0 in Q2 2022.
  • The 4-year median for Other financing activities is -$80000.0 (2025), against an average of -$21923.1.
  • The largest YoY upside for Other financing activities was 154.55% in 2024 against a maximum downside of 870.83% in 2024.
  • A 4-year view of Other financing activities shows it stood at $1.1 million in 2022, then crashed by 97.75% to $24000.0 in 2023, then crashed by 870.83% to -$185000.0 in 2024, then plummeted by 54.05% to -$285000.0 in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Other financing activities are -$285000.0 (Q3 2025), $118000.0 (Q2 2025), and -$80000.0 (Q1 2025).